News

Learn more about how C3i takes part in the development of new cell and gene therapies.
  • May 11, 2025

    C3i at ISCT 2025: An International Showcase for Our CDMO Capabilities

    A strategic gathering at the crossroads of innovation, regulation, and global partnerships From May 7 to 10, 2025, C3i participated in the International Society for Cell & Gene Therapy (ISCT), a major global conference held this year in New Orleans. Bringing together leading experts and organizations in the field, ISCT serves as a key hub […]

    Read More
  • May 09, 2025

    C3i Wins the 2025 Orchidée Innovation Award at the ESTim Gala

    A recognition of innovation serving health and the community C3i Center is proud to have received the Prix Orchidée Innovation 2025, presented by the Chambre de commerce de l’Est de Montréal (CCEM) during the ESTim Gala held on May 8. This prestigious award celebrates our ability to turn bold ideas into tangible solutions that advance […]

    Read More
  • May 01, 2025

    C3i at Effervescence Montréal 2025: A Must-Attend Event for Innovative Therapies

    An active presence at the heart of discussions on regenerative medicine On April 30, Yvan Côté, President and CEO of C3i, took part in Effervescence Montréal 2025, a key event bringing together key players from research, innovation, and the life sciences industry. Organized by ThéCell – Québec’s Cell, Tissue and Gene Therapy Network, this year’s […]

    Read More
  • Apr 29, 2025

    C3i Meets the Next Generation of Scientists at INRS

    An inspiring presentation on the role of CDMOs in Québec’s biotechnology ecosystem On Monday, April 28, C3i had the pleasure of presenting its mission and expertise at INRS – Institut national de la recherche scientifique, specifically at the Armand-Frappier Santé Biotechnologie Research Centre, located in Laval. This cutting-edge center is renowned for contributing to biomedical […]

    Read More
  • Apr 09, 2025

    C3i Attends the 2025 Cancer Immunotherapy Summit in Toronto

    A key moment of networking and collaboration to advance research C3i was pleased to participate in the Summit for Cancer Immunotherapy, held from April 6 to 8, 2025, in Toronto, a major event organized by BioCanRx. This annual summit brings together researchers, clinicians, patient partners, and industry leaders to discuss progress in cancer immunotherapy and […]

    Read More
  • Mar 24, 2025

    A Deep Dive into Flow Cytometry

    Precision-Driven Flow Cytometry: Advanced Technologies Ensuring Reliable Data for Complex Therapies. All flow cytometry assays performed in C3i are qualified and/or validated. Depending on the assays, three instruments are currently used: FACS Lyric, FACS Canto, or Accellix. During the qualification/validation, accuracy is verified using a known control (where reference values have already been established). Reproducibility […]

    Read More
  • Mar 10, 2025

    C3i announces the promotion of Julie Artigalas to Senior Manager – Client Accounts

    C3i is pleased to announce the promotion of Julie Artigalas to the position of Senior Manager – Client Accounts. This promotion marks a key milestone in our ongoing commitment to delivering strategic support and high-quality service to our partners, and reflects the significant impact Julie has had on the management of our clinical projects. Holding […]

    Read More
  • Feb 19, 2025

    C3i Center receives approval from the EMA to manufacture cell therapy products for the European market.

    C3i announces that it has obtained regulatory approval from the EMA (European Medicine Agency) to produce cell therapy treatments for the European market. The company received a certificate of Good Manufacturing Practice (GMP) compliance following an inspection of their Montreal facility by the European Medicines Agency. Therefore, C3i obtains a certificate of GMP (Good Manufacturing […]

    Read More
  • Jan 28, 2025

    C3i was proud to participate in Advanced Therapies Week, which took place in Dallas from January 20 to 23, 2025.

    As a key event in the biotech industry, ATW 2025 gathered 2,500 attendees, 100 investors, 600 biotech companies, and 180 exhibitors at the Kay Bailey Hutchinson Convention Center. With six content tracks and 250 expert speakers, the event fostered innovation, regulatory discussions, and strategic collaborations to advance the future of cell and gene therapies. This […]

    Read More